Drugdocs | Gavreto

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Gavreto

Chemical Name	pralsetinib
Dosage Form	Capsules (oral; 100 mg)
Drug Class	Kinase inhibitors
System	Respiratory
Company	Blueprint Medicines
Approval Year	2020

Indication

To treat adult patients with non-small cell lung cancer (NSCLC) which has spread to other parts of the body (metastatic) and is caused by abnormal RET (rearranged during transfection) genes.

Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Gavreto (pralsetinib) Prescribing Information.	2020	Blueprint Medicines Corporation, Cambridge, MA

Document Title	Year	Source
AcceleRET lung: a phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced/metastatic non-small cell lung cancer (NSCLC).	2020	Journal of Clinical Oncology

Document Title	Year	Source
Treating Non-Small Cell Lung Cancer.	2020	American Cancer Society